DUBLIN--(BUSINESS WIRE)--The "Investigation Report on China's Liraglutide Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Novo Nordisk A/S. Its product VICTOZA firstly launched in the EU in July 2009 and firstly approved to enter the Chinese market in 2011.
Liraglutide is a medication used for the treatment of type 2 diabetes or obesity. As one of the most important GLP-1 receptor agonists, Liraglutide is the only human GLP-1 analog that has been shown to reduce the risk of cardiovascular death. By 2020, Novo Nordisk A/S is the only manufacturer in the Chinese Liraglutide market.
According to the market research, Liraglutide sales have increased year by year from 2016 to 2020. Liraglutide was included in the medical insurance reimbursement catalog in 2017. Therefore, the sales value growth in 2018 was the most obvious, from CNY51.98 million in 2017 to CNY114.39 million in 2018.
The annual growth rate is about 120.05%. Due to the impact of the COVID-19 epidemic, the sales value of China's Liraglutide reached CNY286.73 million in 2020 and the growth rate is 30.43%, which is less than that in 2019. The CAGR of Liraglutide's sales value from 2016 to 2020 is 61.87% in China.
The analyst expects that the sales value of Liraglutide will have a recovery growth from 2021 to 2025 with the effective alleviation of the COVID-19 epidemic. The patent of Liraglutide has expired, and the drug registration application for Liraglutide injection produced by Shenzhen Hanyu Pharmaceutical Co., Ltd. has been officially accepted in 2019.
Since then, the number of manufacturers will gradually increase, the market will continue to expand, and the price will decline, which will cause the increase in sales and sale volume of Liraglutide. In addition, the huge patient population will also enable the Liraglutide market to continue to expand.
In China, on average, there is 1 diabetic in 10 adults, and type 2 diabetic patients account for more than 90% of all diabetic patients. The huge number of patients has also increased the demand for Liraglutide. Therefore, its sales will continue to grow as the market expands in the future.
Topics Covered:
- The impact of COVID-19 on China's Liraglutide market
- Sales value of China's Liraglutide 2016-2020
- Competitive landscape of China's Liraglutide market
- Prices of Liraglutide in China
- Prices of Liraglutide in China by regions and manufacturers
- Analysis of factors affecting the development of China's Liraglutide market
- Prospect of China's Liraglutide market from 2021 to 2025
Key Topics Covered:
1 Relevant Concepts of Liraglutide
1.1 Indications for Liraglutide
1.2 Development of Liraglutide in China
1.3 Governmental Approval of Liraglutide in China
1.4 The Impact of COVID-19 on Liraglutide sales in China
2 Sales of Liraglutide in China, 2016-2020
2.1 Sales Value of Liraglutide
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Liraglutide
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Liraglutide by Dosage Form in China, 2016-2020
2.3.1 Injection
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Liraglutide Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Liraglutide Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Novo Nordisk A/S
3.2.1 Enterprise Profile
3.2.2 Sales of VICTOZA (Novo Nordisk A/S's Liraglutide) in China
4 Prices of Liraglutide for Different Manufacturers in China, 2020-2021
4.1 Novo Nordisk A/S (VICTOZA)
4.2 Analysis of Other Enterprises
5 Prospect of Chinese Liraglutide drug Market, 2021-2025
5.1 Influential Factors of Chinese Liraglutide Market Development
5.1.1 The Impact of COVID-19 on Chinese Liraglutide Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
For more information about this report visit https://www.researchandmarkets.com/r/t743f1
